secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2021-10-12T23:59:59+00:00
Accession:  0001193125-21-296407
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics appoints Kathleen Tregoning to Board; Jean-François Formela resigns
--------------------------------------------------------------------------------

- Jean-François Formela resigned from the Board effective Oct 11, 2021, as part of a planned transition.
- Kathleen Tregoning appointed to fill the vacancy, effective Oct 11, 2021.
- Tregoning brings over 20 years of biotech and public policy experience; currently Chief Corporate Affairs Officer at Cerevel Therapeutics.
- Former executive at Biogen and Sanofi, and former congressional staff member.
- Tregoning will serve as Class III director up for reelection at 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/0001193125-21-296407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312521296407/d227095d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-296407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer